Search results for " non-muscle invasive bladder cancer"

showing 2 items of 2 documents

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

2013

Objective To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non–muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy. Methods Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing 2 different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80 mg/50 mL) within 6 hours after TUR, followed by 5 more weekly instillations with (arm B) or without (arm A) monthly instillations for 1 year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariat…

AdultMalemedicine.medical_specialtyMultivariate analysisTime Factorsintravesical chemotherapy non-muscle invasive bladder cancerUrologymedicine.medical_treatmentcigarette smokingKaplan-Meier EstimateCystectomyGastroenterologyDisease-Free SurvivalSettore MED/24 - UrologiaCystectomyCigarette smokingRisk FactorsMulticenter trialInternal medicinemedicineCarcinomaHumansAgedEpirubicinProportional Hazards ModelsAged 80 and overAntibiotics AntineoplasticProportional hazards modelbusiness.industryCarcinomaSmokingMiddle AgedFormer Smokermedicine.diseaseintermediate-risk tumorrecurrence.Combined Modality TherapySurgeryUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessEpirubicinmedicine.drug
researchProduct

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

2016

Abstract Background The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n = 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients no…

Malemedicine.medical_specialtymedicine.drug_classUrology030232 urology & nephrologyLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansAntiplateletStage (cooking)Macroscopic hematuriaAnticoagulant; Antiplatelet; Bladder cancer; Emergency room; Hematuria; Non-muscle invasive bladder cancerEarly Detection of CancerRetrospective StudiesHematuriaAgedNeoplasm StagingBladder cancerbusiness.industryPlatelet Aggregation InhibitorAnticoagulantBladder cancerAnticoagulantAnticoagulantsRetrospective cohort studyEmergency roomOdds ratioMiddle Agedmedicine.diseaseSurgeryUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmPlatelet aggregation inhibitorFemalebusinessNon-muscle invasive bladder cancerPlatelet Aggregation InhibitorsHuman
researchProduct